Concepedia

Naval Daver

ND

Statistics

Publications

382

Citations

22.2K

H-Index

77

Active since

2005

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of California, Irvine

Moffitt Cancer Center

Dana-Farber Cancer Institute

Roswell Park Comprehensive Cancer Center

Naval Daver is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematology.

ORCID

Top concepts

Publications per year

2005–2025

382

Publications

382

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 903 citations · Full text

, , +4

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Naval Daver, Guillermo Garcia‐Manero, Sreyashi Basu et al. · Cancer Discovery · 2018 · 559 citations

Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton et al. · American Journal of Hematology · 2017 · 429 citations · Full text

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald et al. · Blood · 2013 · 373 citations · Full text

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Timothy A. Yap, Naval Daver, Mikhila Mahendra et al. · Nature Medicine · 2023 · 335 citations · Full text

, , +8

1–5 of 382